Unclassified · NSE: DRREDDY
Dr. Reddy's Laboratories share analysis
Fair value, business quality, the case for and against, and the risks — computed by VestCall from reported data, updated 14 October 2026.
Dr. Reddy's Laboratories in one paragraph
Dr. Reddy's Laboratories (NSE: DRREDDY) was trading at ₹1,223.7 on 14 October 2026. VestCall scores its business health 49/100 (weak). On valuation, the price sits in the “Fairly Valued” zone (₹1,197.74 – ₹1,229.84) — inside the modelled fair-value range. This is a reading of the evidence, not a buy or sell recommendation.
- Share price₹1,223.7
- Business health49/100
- Growth11/100
- Financial strength71/100
- Valuation65/100 · Fair
- Valuation zoneFairly Valued
- RiskMedium
Is Dr. Reddy's Laboratories overvalued or undervalued?
At ₹1,223.7, Dr. Reddy's Laboratories sits in VestCall’s “Fairly Valued” zone (₹1,197.74 – ₹1,229.84): inside the modelled fair-value range. Its valuation scores 65/100 (fair) against Unclassified peers. Zones describe where the price sits against modelled value; they are not an instruction to buy or sell.
| Valuation zone | Price band | What it means |
|---|---|---|
| Deeply Discounted | ₹1,118.79 – ₹1,182.15 | Furthest below the modelled fair-value range |
| Attractive Valuation | ₹1,182.15 – ₹1,197.74 | Below the modelled fair-value range |
| Fairly Valued (current) | ₹1,197.74 – ₹1,229.84 | Inside the modelled fair-value range |
| Valuation Premium | ₹1,229.84 and above | Above the modelled fair-value range |
The case for and against Dr. Reddy's Laboratories
What supports the case
- Financial Strength · 71/100.
- Shareholding Quality · 71/100.
- Capital Allocation · 63/100.
What needs proof
- Growth · 18/100.
- Management Stability · 51/100.
- Business Quality · 59/100.
Dr. Reddy's Laboratories key ratios
| Ratio | Dr. Reddy's Laboratories | Unclassified median |
|---|---|---|
| P/E | 15.38x | — |
| P/B | 1.59x | — |
| P/S | 1.43x | — |
| Return on equity (ROE) | 13.3% | — |
| Return on capital employed (ROCE) | 17.2% | — |
| Operating margin | 15.4% | — |
| Net margin | 11.9% | — |
| Current ratio | 1.66x | — |
Dr. Reddy's Laboratories growth
Growth scores 11/100, with a negative trend, measured Mar 2023 to Mar 2026.
| Measure | Reading |
|---|---|
| Revenue CAGR | 10.9% |
| Net profit CAGR | -2.7% |
| EPS CAGR | -43.0% |
| Revenue growth, latest year | 3.9% |
| Profit growth, latest year | -27.4% |
Dr. Reddy's Laboratories bull, base and bear case
Modelled annual return under three sets of stated assumptions over 5 years. These are model outputs, not a forecast or a promise of return.
| Scenario | Modelled CAGR | Weight | Assumption |
|---|---|---|---|
| Bear | −8.3% | 19% | Growth decelerates to -4.3% and the multiple de-rates toward the cohort's trough. |
| Base | +0.5% | 55% | Earnings compound near the measured 0.5% and the multiple drifts toward its quality-adjusted warranted level. |
| Bull | +7.0% | 26% | Growth holds at 3.5% and the market pays the full premium the measured quality supports. |
Risks to watch in Dr. Reddy's Laboratories
| Review trigger | Current | Threshold | Status |
|---|---|---|---|
| Return on equity falls below the quality floor | 13.26% | below 15% | high · breached |
| Revenue growth falls below the thesis floor | 10.87% | below 8% | high · armed |
| Promoter holding drops materially | 26.64% | below 23.64%, 3 points under the Mar 2026 filing | high · armed |
| Price runs more than two sigma above its own trend | 1223.7 | at or above 1731.98 | medium · armed |
| Drawdown from the 52-week high exceeds tolerance | 11.05% | at or beyond 25% | low · armed |
| Leverage doubles from the level underwritten today | No leverage line in the balance sheet | unavailable | high · unmeasurable |
| Promoter pledge rises above tolerance | No pledge disclosed (the NSE filing for DRREDDY could not be read either (nse_session_unavailable)) | above 10% | high · unmeasurable |
| Valuation reaches the top of its own cohort | No cohort multiple to rank against | at or above the 95th percentile | medium · unmeasurable |
An armed trigger is watched and has not fired; a breached one has.
How Dr. Reddy's Laboratories shares have traded
| Measure | Reading |
|---|---|
| 52-week range | ₹1,135.6 – ₹1,375.7 |
| Distance from 52-week high | −11.1% |
| Return, 3 months | −1.8% |
| Return, 12 months | −2.0% |
| Trend | Downtrend |
| Annualised volatility | 22.0% |
| Deepest drawdown, 2 years | −23.0% |
Questions about Dr. Reddy's Laboratories shares
Is Dr. Reddy's Laboratories overvalued or undervalued?
At ₹1,223.7, Dr. Reddy's Laboratories sits in VestCall’s “Fairly Valued” zone (₹1,197.74 – ₹1,229.84): inside the modelled fair-value range. Its valuation scores 65/100 (fair) against Unclassified peers. Zones describe where the price sits against modelled value; they are not an instruction to buy or sell.
Is Dr. Reddy's Laboratories fundamentally strong?
VestCall scores Dr. Reddy's Laboratories’s business health 49/100 (weak). The strongest measured pillars are financial strength and shareholding quality. The ones that need proof are growth and management stability. Each pillar is computed from reported financials, and a pillar whose inputs were not reported is excluded rather than scored as zero.
What is Dr. Reddy's Laboratories’s P/E ratio?
Dr. Reddy's Laboratories trades at a P/E of 15.38x, on VestCall’s latest read. A multiple only means something against the business it buys: the quality-adjusted fair value on this page weighs it against Dr. Reddy's Laboratories’s returns and growth.
What are the risks of investing in Dr. Reddy's Laboratories?
The review triggers VestCall watches for Dr. Reddy's Laboratories are: return on equity falls below the quality floor (roe below 15%); revenue growth falls below the thesis floor (revenue cagr below 8%); promoter holding drops materially (promoter holding below 23.64%, 3 points under the Mar 2026 filing). On the fundamentals, growth is the weakest measured pillar at 18/100. A trigger is a named condition that would change the reading, published so the case against the stock is as visible as the case for it.
Is this a recommendation to buy or sell Dr. Reddy's Laboratories?
No. VestCall states where Dr. Reddy's Laboratories’s price sits against modelled value, what supports the case and what would break it, with every figure sourced. It does not issue buy, sell or hold calls or price targets. Vestmind is not a SEBI-registered investment adviser or research analyst, and nothing on this page is personalised investment advice.
Compare with other companies in Healthcare
Read the full Dr. Reddy's Laboratories analysis
Every score opens into its signals, the valuation into its anchors and workings, and the statements are one click away. Free, no account needed.